A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy

Anti-Cancer Drugs

Volumn 24, Issue 7, 2013, Pages 743-753

  Twardowski, Przemyslaw W ^a   Beumer, Jan H ^e   Chen, C S ^b   Kraft, Andrew S ^f   Chatta, Gurkamal S ^e   Mitsuhashi, Masato ^c   Ye, Wei ^a   Christner, Susan M ^e   Lilly, Michael B ^d  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b LOMA LINDA UNIVERSITY HEALTH   (United States)

^c Hitachi Chemical Research Center   (Japan)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

dasatinib; prostate cancer; SRC inhibition

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; ATRASENTAN; CARBOPLATIN; CD40 LIGAND; DASATINIB; DOCETAXEL; ETOPOSIDE; INTERLEUKIN 2; INTERLEUKIN 6; PHYTOHEMAGGLUTININ; PROSTATE SPECIFIC ANTIGEN; ZOLEDRONIC ACID;

ADULT; AGED; ANEMIA; ARTICLE; BONE SCINTISCANNING; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CASTRATION RESISTANT PROSTATE CANCER; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG RESPONSE; DRUG TOLERABILITY; DYSPNEA; ELECTROCORTICOGRAPHY; FATIGUE; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPONATREMIA; LIFE EXPECTANCY; METASTASIS; PERICARDIAL EFFUSION; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; QUALITY OF LIFE; SIDE EFFECT; T LYMPHOCYTE; TREATMENT DURATION; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VEIN THROMBOSIS;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; ORCHIECTOMY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEIN KINASE INHIBITORS; PYRIMIDINES; TESTOSTERONE; THIAZOLES; TREATMENT OUTCOME;

EID: 84879957661     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328361feb0     Document Type: Article

References (32)

1. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-422.
2. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502-1512.
3. De Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Koxak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet 2010; 376:1147-1154.
4. Parker Chris, Nilsson Sten, Heinrich Daniel, O'Sullivan Joe M, Fossa Sophie D, Oliver Sartor A, et al. Updated analysis of the phase III, doubleblind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA) [abstract]. J Clin Oncol 2012; 30 (Suppl):LBA4512.
5. Bono Johann SebastianDe, Fizazi Karim, Saad Fred, Taplin Mary-Ellen, Sternberg Cora N, Miller Kurt, et al. Primary, secondary, and quality-of-life endpoint results from the phase III AFFIRM study of MDV3100, an androgen receptor signaling inhibitor [abstract]. J Clin Oncol 2012; 30 (Suppl):4519.
6. De Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364:1995-2005.
7. Hellawell GO, Brewster SF. Growth factors and their receptors in prostate cancer. BJU Int 2002; 89:230-240.
8. Frame MC. Src in cancer: deregulation and consequences for cell behavior. Biochim Biophys Acta 2002; 160:114-130.
9. Warmuth M, Damoiseaux R, Liu Y, Fabbro D, Gray N. Src family kinases: potential targets for the treatment of human cancer and leukemia. Curr Pharm Des 2003; 9:2043-2059.
10. Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, Mancini MA, et al. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Cancer Res 2004; 64:7156-7168.
11. Gray MJ, Zhang J, Ellis LM, Semenza GL, Evans DB, Watowich SS, et al. HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene 2005; 24:3110-3120.
12. Finn RS, Dering J, Wilson CA, Glaspy P, Tchmedyian N, Yang G, et al. Biologic effects and identification of predictive markers of response to dasatinib (BMS-354825), a novel, oral, multitargeted kinase inhibitor in human breast cancer cell lines in vitro. Abstract A233, AACR-NCI-EORTC Int'l Conference on Molecular Targets and Cancer Therapeutics. Philadelphia, PA; 2005.
13. Nam S, Kim D, Cheng JQ, Zhang S, Lee JH, Buettner R, et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005; 65:9185-9189.
14. Yu EY, Wilding G, Posadas E, Gross M, Culine S, Massard C, et al. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin.Cancer Res 2009; 15:7421-7428.
15. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the PSA Working Group. J Clin Oncol 1999; 17:3461-3467.
16. Scher H, Halabi S, Tannock I, Morris M, Sternberg C, Carducci M, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26:1148-1159.
17. Mitsuhashi M. Ex vivo stimulation of leukocyte function: stimulation of specific subset of leukocytes in whole blood followed by the measurement of function-associated mRNAs. J Immunol Methods 2010; 363:95-100.
18. Finn RS, Bengala C, Ibrahim N, Roché H, Sparano J, Strauss LC, et al. Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study. Clin Cancer Res 2011; 17:6905-6913.
19. Mayer EL, Baurain JF, Sparano J, Strauss L, Campone M, Fumoleau P, et al. A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer. Clin Cancer Res 2011; 17:6897-6904.
20. Araujo J, Trudel G, Saad F, Armstrong A, Yu E, Belmunt J, et al. Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): results of randomized phase III READY trial [abstract]. J Clin Oncol 2013; 31 (Suppl 6):LBA8.
21. Hantschel O, Rix U, Superti-Furga G. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma 2008; 49:615-619.
22. Hantschel O, Rix U, Schmidt U, Burckstummer T, Kneidinger M, Schutze G, et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci USA 2007; 104:13283-13288.
23. Kawakami Y, Kitaura J, Satterthwaite AB, Kato RM, Asai K, Hartman SE, et al. Redundant and opposing functions of two tyrosine kinases, Btk and Lyn, in mast cell activation. J Immunol 2000; 165:1210-1219.
24. Lara PN Jr, Longmate J, Evans CP, Quinn DI, Twardowski P, Chatta G, et al. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anticancer Drugs 2009; 20:179-184.
25. Dai G, Pfister M, Blackwood-Chirchir A, Roy A. Importance of characterizing determinants of variability in exposure: application to dasatinib in subjects with chronic myeloid leukemia. J Clin Pharmacol 2008; 48:1254-1269.
26. Lilly MB, Ottmann OG, Shah NP, Larson RA, Reiffers JJ, Ehninger G, et al. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: results from a phase 3 study. Am J Hematol 2010; 85:164-170.
27. Noens L, van Lierde MA, De Bock R, Verhoef G, Zachée P, Berneman Z, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009; 113:5401-5411.
28. Ibrahim AR, Eliasson L, Apperley JF, Milojkovic D, Bua M, Szydlo R, et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood 2011; 117:3733-3736.
29. Domingo-Domenech J, Oliva C, Rovira A, Codony-Servat J, Bosch M, Filella X, et al. Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity. Clin Cancer Res 2006; 12:5578-5586.
30. Anderson KC. Lenalidomide and thalidomide: mechanisms of action-similarities and differences [review]. Semin Hematol 2005; 42 (Suppl 4):S3-S8.
31. Waldner MJ, Foersch S, Neurath MF. Interleukin-6-a key regulator of colorectal cancer development. Int J Biol Sci 2012; 8:1248-1253.
32. Mendiratta P, Mostaghel E, Guinney J, Tewari AK, Porrello A, Barry WT, et al. Genomic strategy for targeting therapy in castration-resistant prostate cancer. J Clin Oncol 2009; 27:2022-2029.